Advocacy intelligence hub — real-time data for patient organizations
argenx — PHASE3
Dianthus Therapeutics — PHASE2
Assistance Publique - Hôpitaux de Paris
IRCCS San Camillo, Venezia, Italy — NA
argenx
argenx — PHASE2
Gammagard Liquid: FDA approved
Maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Gammagard Liquid
Takeda Pharmaceuticals U.S.A., Inc.
Gammagard Liquid
(immune globulin infusion (human))Orphan drugTakeda Pharmaceuticals U.S.A., Inc.
Jean-Marc LEGER, MD
Hôpital de la Pitié Salpêtrière - Paris 75013
Matthias Sturzenegger, MD
Inselspital, University Hospital of Bern
Giancarlo Comi, MD
San Raffaele Hospital
Siraj Misbah, MD
Dept. Clinical Immunology, Oxford Radcliffe Hospitals
Johannes Jakobsen, DMSc
Neuroscience Center, Rigshospitalet
Bernd Kieseier, MD
Neurologische Klinik, Heinrich-Heine-University, Düsseldorf